Background
==========

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder in which selective loss of motor neurones in the cerebral cortex, brainstem and spinal cord leads to progressive paralysis. In the majority of cases of ALS, the cause of motor neurone degeneration is unknown, although a number of pathogenic processes, including oxidative stress, excitotoxicity, inflammation, and mitochondrial and neurofilament dysfunction, are thought to play important roles. Ten percent of cases of ALS are familial, and in 20% of these, a causative mutation is found in the gene encoding superoxide dismutase I (SOD1), a free radical scavenger. In the SOD1 rodent model of ALS, overexpression of human mutant SOD1 causes adult onset motor neurone degeneration.

Vascular endothelial growth factor (VEGF) is an endothelial cell mitogen that stimulates angiogenesis in response to hypoxia, in the developing embryo and in a number of pathological conditions, such as tumour growth. VEGF transcription is upregulated by binding of hypoxia inducible factor (HIF-1) to a hypoxia response element (HRE) in the 5\' promoter region of the gene. In 2001, Oosthuyse *et al*deleted the HRE of the VEGF gene in mice, to generate VEGF^δ/δ^mice \[[@B1]\], which express reduced levels of Vegf in neural tissue under both baseline and hypoxic conditions. VEGF^δ/δ^mice show 60% mortality at or around birth, and surviving transgenic mice are slightly smaller than their wild-type littermates. At 5 months of age, they develop a motor neurodegenerative phenotype that resembles ALS, with impairment of motor behaviours and motor tests, such as the treadmill test. Electrophysiological studies show signs of denervation and compensatory reinnervation, muscle histology shows neurogenic atrophy, and peripheral nerves show loss of large myelinated motor axons. In the spinal cord and brainstem, similar numbers of motor neurones are present until 3 months of age, but by 17 months, there is a 30% reduction in motor neurone numbers, with a reactive astrocytosis, and neurofilament inclusions in surviving neurones \[[@B1]\]. The mechanism of neurodegeneration in VEGF^δ/δ^mice is unknown. Chronic hypoxia has been proposed, as although vascular structure in the sciatic nerve and spinal cord is normal, baseline neural blood flow is reduced by 44%. In addition to vascular development, however, VEGF plays a central role in the development of the nervous system, and may be required for survival of adult neurones \[[@B2]\]. Disruption of these functions may determine the development of neuronal degeneration in VEGF^δ/δ^mice.

VEGF has neurotrophic effects *in vitro*in a wide range of culture conditions, promoting cell survival and neurite outgrowth, via its tyrosine kinase receptor, VEGFR2 \[[@B3]\]. *In vivo*, VEGF administration prolongs survival in the SOD1 model of ALS \[[@B4]\]. This is likely to be a direct neuroprotective effect, as SOD1 mice crossed with mice with neuronal overexpression of VEGFR2 also exhibit delayed disease progression \[[@B5]\]. In the developing nervous system, VEGF released by neuroblasts and glia induces the ingrowth of capillaries, and deletion of a single copy of VEGF is lethal \[[@B6],[@B7]\]. VEGF stimulates neurogenesis directly \[[@B8]\], and via endothelial cell proliferation, to form vascular niches in which neurogenesis is stimulated by endothelial-derived BDNF \[[@B9],[@B10]\]. Further interaction between vascular and neuronal development is seen in the closely aligned growth of blood vessels and peripheral nerves, directed by attractive and repulsive cues on the growth cone \[[@B11]\]. The VEGF co-receptor, Neuropilin-1 mediates both repulsive signals of the semaphorin family, and attractant signals of VEGF \[[@B11],[@B12]\]. Thus VEGF, with its angiogenic and neurotrophic actions via VEGFR2, and shared receptor with the semaphorin axon guidance factors, may be a key player in the parallel development of vascular and nervous systems.

A recent meta-analysis of association studies of VEGF polymorphisms with ALS showed an increased risk of ALS in male patients with the -2578AA genotype, which lowers VEGF expression\[[@B13]\]. We have previously shown that levels of expression of VEGF and its main agonist receptor are reduced in the spinal cord of patients with ALS\[[@B14]\]. This study aims to clarify the molecular mechanisms of neurodegeneration in the VEGF^δ/δ^mouse, by determination of the transcriptional profile of isolated spinal motor neurones in the transgenic mouse, compared to its wild type littermate. Understanding the role of VEGF in the survival and death of motor neurones in this mouse model of ALS may have implications for the human disease.

We report that adult VEGF^δ/δ^mice show reduction in expression, from symptom onset, of genes involved in nervous system development, particularly in axonogenesis and synapse formation, and that axon outgrowth is reduced in motor neurone cultures derived from VEGF^δ/δ^mice. These changes suggest a role for VEGF in the maintenance of neuronal circuitry, disruption of which may result in a dying-back axonopathy.

Methods
=======

Experimental animals
--------------------

Adult female VEGF^δ/δ^mice and wild type littermates (Vesalius Research Institute, Leuven, Belgium) were used in this study. VEGF^δ/δ^mice, on a Swiss/129 background, had homozygous deletion of the HIF-1 response element (hypoxia response element) in the promoter region of the VEGF gene, and were generated as previously described \[[@B1]\]. All mice were housed in conventional facilities with a 12 h light/dark cycle with access to food at libitum. The local animal ethical committee, the Ethische Commissie Dierproeven (ECD) at the Catholic University Leuven, Belgium, approved the VEGF^δ/δ^mouse experiments.

Tissue collection
-----------------

Three female VEGF^δ/δ^transgenic mice, and three gender-matched wild-type littermate controls were sacrificed at 3 months (pre-symptomatic), 5 months (onset of symptoms) and 14 months (late stage disease) of age, by overdose of isoflurane inhalational anaesthetic. Post mortem, animals were perfused by intracardiac injection of 15 ml sterile phosphate buffer with 30% sucrose, and the CNS was dissected and frozen in Cryo-M-Bed embedding compound (Bright, Huntingdon, UK). The procedure of sucrose perfusion and dissection of the spinal cord was conducted rapidly, within a maximum of ten minutes from terminal anaesthesia to snap freezing of tissue, to ensure optimal preservation of RNA quality. Lumbar spinal cord sections (10 μm) were fixed in 70% ethanol, washed in DEPC-treated water, and stained for 1 minute in a solution of 0.1% w/v Toluidine Blue in 0.1 M sodium phosphate. They were then washed and dehydrated through graded ethanol concentrations (70, 90 and 100%), and xylene.

Laser capture microdissection, RNA isolation and amplification
--------------------------------------------------------------

Spinal motor neurones, identified by staining, anatomical location, size and morphology, were isolated on Capsure Macro LCM caps using the Arcturus PixCell II laser capture microdissection system (Arcturus Bioscience, Mountain View, CA). Approximately 1500 motor neurones were dissected from each spinal cord, and \>50 ng RNA extracted using the PicoPure™ RNA isolation kit (Arcturus), according to manufacturer\'s instructions. RNA amplification was carried out using a linear amplification process in 2 cycles, with the GeneChip two cycle target labelling and control kit (Affymetrix, Santa Clara, USA), and MEGAscript^®^T7 kit (Ambion, Austin, USA). The linear amplification technique has been shown to generate highly reproducible gene expression profiles from small starting quantities of RNA \[[@B15]\]. This procedure produced 50-100 μg of biotin labelled antisense RNA for each sample, the quality and quantity of which was assayed using the Agilent bioanalyser and Nanodrop™ 1000 spectrophotometer (Thermo Scientific, Wilmington, USA).

Quality control parameters
--------------------------

At each stage of extraction, amplification and microarray analysis, we carried out quality control (QC) measures, according to Affymetrix protocols, to ensure that RNA was of sufficient quality and was matched between samples. Where QC outliers were identified, these samples were excluded from the analysis. We used visual interpretation of RNA profiles from bioanalyser traces of extracted and amplified RNA to determine RNA quality, as the 28S:18S ratio has been shown to have only weak correlation with gene expression levels in downstream experiments\[[@B16]\]. The RNA profiles obtained from laser captured material in this study were comparable to profiles with modest RNA degradation, that has been shown to have little effect on the results of microarray analysis \[[@B17],[@B18]\] (Figure [1](#F1){ref-type="fig"}) Following amplification, the most frequent length of RNA amplicons, at 500-1000 kB, was consistent with Affymetrix protocols. Affymetrix and Bioconductor software was used to generate, from microarray data, the QC measures of average background, signal intensity, percent present calls, and RNA degradation plots, to ensure that samples were comparable in all parameters.

![**Representative bioanalyser traces of RNA samples pre- and post-amplification at 3 months, 5 months and 14 months**.](1471-2164-11-203-1){#F1}

Affymetrix GeneChip processing
------------------------------

15 μg amplified cRNA was fragmented by heating to 94°C for 20 minutes, and spiked hybridization controls were added. Each sample was hybridized to one mouse 430A2 GeneChip (Affymetrix) according to manufacturer\'s protocols. Following overnight hybridization at 42°C, GeneChips underwent stringency washes in a Fluidics Station 400, then were scanned in the GeneChip Scanner 3000 to detect fluorescent hybridization signals. These were analysed by the Affymetrix GeneChip Operating System (GCOS) to generate an overall hybridization signal for each transcript from 11 representative perfect match and mismatch probe pairs.

Microarray data analysis
------------------------

CEL files generated by GCOS were imported for further analysis into Array Assist software (Stratagene, La Jolla, USA), where probe level analysis was carried out using the GC Robust Multichip Average (GC-RMA) algorithm. Following GCRMA processing, data was filtered to remove those genes whose expression was at or around the background signal level of the chip. Any probe set that returned a signal of \<50 on more than 3 chips at each time point was excluded from further analysis. This signal filter did not remove genes that were only expressed in one experimental group. Differential gene expression was determined using an unpaired t-test, to generate a list of genes that were significantly differentially expressed between transgenic mice and their wild type littermates, at each time point.

Gene ontology analysis
----------------------

Gene Ontology (GO) terms that reflect the function of the corresponding genes are assigned to each probe set by Affymetrix software. This GO information was used to determine which functionally related groups of genes were over-represented amongst significantly differentially expressed genes at each time point. The frequencies of GO terms represented in the significant gene lists were compared to a denominator list of genes that can be expressed by motor neurones in health or disease. GO analysis was carried out without regard for fold change, in order to limit type II errors and in order to detect more subtle changes in gene expression, for example in transcriptional regulators, which may be biologically significant. The denominator list was generated from the array data for each time point, by extracting those genes whose representative probe sets returned a signal of \>50 in 3 or more chips. Statistical analysis of GO term enrichment was carried out using DAVID software (NIAID/NIH; <http://david.abcc.ncifcrf.gov/summary.jsp>, \[[@B19]\]. Literature review was also used to identify significantly differentially expressed genes with functions relating to those identified as enriched by DAVID analysis.

Verification of microarray results by Quantitative rt-PCR (QPCR)
----------------------------------------------------------------

A proportion of genes identified as significantly differentially expressed were selected for verification by QPCR, on the basis of robust microarray data confirming differential gene expression, involvement in a biological process identified as enriched by GO analysis, or a known function in neurodegeneration. Verification addresses the possibility of false positive microarray signals, due to cross-hybridization with related genes, concern about the accuracy of array probe sets, and uncertainty about the hybridization kinetics of multiple reactions occurring on the miniature scale of an array chip. RNA was extracted from 1000-1500 cells, isolated by laser capture microdissection from the lumbar spinal cord of the population of mice used in the microarray experiment and, where available, a second population of transgenic mice with wild-type littermates. RNA was extracted, quantified as previously described, and reverse transcribed to cDNA using Superscript II reverse transcriptase, according to manufacturer\'s protocol (Invitrogen, San Diego, CA). Primers used in for verification are shown in Table [1](#T1){ref-type="table"}. QPCR was performed using 12.5 ng cDNA, 1×SYBR Green PCR master mix (Applied Biosystems, Foster City, CA), and forward and reverse primers at optimized concentrations, to a total volume of 20 μl. After an initial denaturation at 95°C for 10 mins, templates were amplified by 40 cycles of 95°C for 15 secs and 60°C for 1 minute, on an MX3000P Real-Time PCR system (Stratagene). A dissociation curve was then generated to ensure amplification of a single product, and absence of primer dimers. For each primer pair, a standard curve was generated to determine the efficiency of the PCR reaction over a range of template concentrations from 0.3 ng/μl to 25 ng/μl, using cDNA synthesized from mouse universal RNA. The efficiency for each set of primers was 100+/-10%, such that gene expression values, normalized to ß-actin expression, could be determined using the ddCt calculation (ABI PRISM 7700 Sequence Detection System protocol; Applied Biosystems). An unpaired t-test was used to determine the statistical significance of any differences in gene expression. β-actin hybridization signals determined by microarray analysis confirmed that there was no significant difference in β-actin expression between wild type and transgenic mice. To determine the effect of the choice of the normalizing gene on the verification of microarray results by QPCR, the expression of four genes was also determined using two alternative normalizing genes, HspB8 and Nme1. These were identified by microarray analysis as having the most consistent levels of expression in spinal motor neurones at each time point, with the lowest coefficient of variation of hybridization signals.

###### 

Primer pairs used for QPCR experiments

  Gene symbol     Forward sequence                  Reverse Sequence                Optimal primer conc F/R (fmol)
  --------------- --------------------------------- ------------------------------- --------------------------------
  **3\' Actin**   GCTCTGGCTCCTAGCACCAT              AGCCACCGATCCACACAGAGT           300/300
  **HspB8**       GGGCCTGCTCATCATCGA                GAGGAAGCTCGTTGTTGAAGCT          300/300
  **Nme1**        CGCAGAACTGGATCTATGAGTGA           CCCCTGCCTGTGAGAACAA             300/300
  **Zfp101**      GGATGAAATCCTGTTCCCATACAT          TGTCCTGGATTAGATACTGTATTTTGATA   900/900
  **Fos**         ATTGTCGAGGTGGTCTGAATGTT           AACGTTTTCATGGAAAACTGTTAATG      300/300
  **Rln**         AAGCACTCGCAAACAAAATTACAT          CCTAAGCGACCTTCGTCTTCTG          900/900
  **HspA5**       CCTCAGAGTGGAGTTGAAAATGCTA         GACCCCAAGACATGTGAGCAA           300/900
  **Ldlr**        ACCTGGCTCGGTTTTCATTCT             AGAGTATCACCCCAGCCTAACCT         900/900
  **Scd1**        GACCAGTCAAAGTGCAAGACTACCTA        AAGGTTTCCTGCAATGGTTTTC          300/300
  **Nrp1**        CGGTAACAACAGGAATCATGTACAA         TTACCCAAATGAAACCAAGAGAAGA       300/300
  **Mtap1B**      CCGTTGCACCTTTCGTAGCT              AGCCAATGCAAGACAAAGGAA           100/100
  **Alcam**       GGACACATATCTTGCCCAATCAG           ATCCTATGGTGCTCCTAACTCTCAA       300/900
  **HNRPDL**      TTGTAAAAGACTTTGTACTCTAGATCAGAGA   TGGCAGCTATATAGACTTCCAGAGA       300/900
  **Tnrc6a**      ATGTTGGACACCGTAACCTAAGC           TATGGACATCAACACACACCGAAT        300/300
  **VEGF**        ATGCTCCCCGGGGTGTAT                CATAGGAGTCCTTCTGACCCATTC        600/600

Neural VEGF quantitation
------------------------

Ten 10 μm sections of cervical cord were taken from each mouse used in the microarray study. RNA was extracted using the PicoPure™ RNA isolation kit (Arcturus) and reverse transcribed to cDNA with Superscript II reverse transcriptase (Invitrogen), according to manufacturer\'s protocols. Neural VEGF expression was assessed by QPCR, as described above, normalized to the expression of ß-actin. Primer sequences and concentrations are shown in Table [1](#T1){ref-type="table"}. VEGF expression was compared between VEGF^δ/δ^and wild-type mice using an unpaired t test.

Isolation of embryonic motor neurons and quantification of axonal outgrowth
---------------------------------------------------------------------------

Cultures of spinal motor neurons from E12.5 mice (VEGF^wt/wt^, n = 8; VEGF^δ/wt^, n = 14; and VEGF^δ/δ^, n = 4) were prepared by a panning technique using a monoclonal anti-p75NTR antibody (Millipore Bioscience Research Reagents)\[[@B20]\]. The ventrolateral parts of individual lumbar spinal cords were dissected and transferred to HBSS containing 10 mM 2-mercaptoethanol. After treatment with trypsin (0.05%, 10 min), single cell suspensions were generated by titration. The cells were plated on an anti-p75NTR coated culture dish (24 well; Greiner) and left at room temperature for 30 min. The individual wells were subsequently washed with HBSS (three times), and the attaching cells were then isolated from the plate with depolarizing saline (0.8% NaCl, 35 mM KCl, and 1 mM 2-mercaptoethanol) and plated at a density of 1500 cells per well on laminin-coated coverslips in Greiner four-well culture dishes. Motor neurons from single embryos were cultured for 7 days in quadruplicates in the presence of BDNF and CNTF (1 ng/ml each, 2000 cells/well initially). Surviving neurons were counted on day 0, 1 and day 7. Initial counting of plated cells was done when all cells were attached to the culture dish at 4 h after plating. At day 7, wells were fixed with fresh 4% paraformaldehyde in phosphate buffer and subjected to immunocytochemistry. Two coverslips with motor neurons of each embryo were stained with antibodies against MAP2 and P-Tau to distinguish between axons and dendrites. Axon lengths of VEGF^wt/wt^(n = 202), VEGF^δ/wt^, (n = 406) and VEGF^δ/δ^(n = 122) neurones were measured using the Leica Confocal Software (Leica, Germany), and compared using a t test.

Results
=======

Neural VEGF expression
----------------------

VEGF^δ/δ^mice used in this study showed a reduction in expression of VEGF mRNA in the cervical spinal cord of 33% compared to their wild type littermates (data not shown). A similar reduction in baseline spinal VEGF protein expression in the spinal cord, although not of mRNA expression, was described by Oosthuyse *et al*\[[@B1]\].

General features of differential gene expression between VEGF^δ/δ^and wild type mice
------------------------------------------------------------------------------------

Between 15 and 18% of probe sets at each time point passed the signal filter, and their corresponding genes were considered expressed by motor neurones. Statistical analysis of these genes showed that 324 genes were significantly differentially expressed (at p \< 0.05 level) between VEGF^δ/δ^and wild type mice at 3 months, 382 genes at 5 months, and 689 genes at late stage. The total numbers of genes which are upregulated and downregulated, with three different p values (0.05, 0.01 and 0.001) are given for each time point in Table [2](#T2){ref-type="table"}. Prior to symptom onset, the majority of differentially expressed genes were upregulated. At disease onset, this pattern had reversed, and the majority of genes were significantly downregulated. At late stage disease there was marked transcriptional downregulation, shown in Figure [2](#F2){ref-type="fig"}. Fold changes between VEGF^δ/δ^mice and their littermates were, in general, smaller than those seen in parallel experimental design using the mutant SOD1 model of ALS \[[@B21]\].

![**Histogram of fold change values of significantly differentially expressed genes at 3 months (green), 5 months (blue) and late stage (red)**. Upregulated genes are plotted on the positive axis, downregulated genes on the negative axis.](1471-2164-11-203-2){#F2}

###### 

Numbers of significantly differentially expressed genes at each time point

  3 months                                                            A[LL]{.smallcaps} FC       \>1.5       \>2                   
  ------------------------------------------------------ ------------ -------------------------- ----------- --------- ------ ---- ------
  **P[ROBE SETS THAT PASS SIGNAL FILTER]{.smallcaps}**                UP                         DOWN        UP        DOWN   UP   DOWN
  6563                                                   p \< 0.05    207                        117         16        27     2    6
                                                         p \< 0.01    26                         28          6         9      1    2
                                                         p \< 0.001   3                          7           2         2      1    1
                                                                                                                                   
  **5 months**                                                        **A[LL]{.smallcaps} FC**   **\>1.5**   **\>2**               
                                                                                                                                   
  **P[ROBE SETS THAT PASS SIGNAL FILTER]{.smallcaps}**                UP                         DOWN        UP        DOWN   UP   DOWN
  7236                                                   p \< 0.05    73                         311         10        138    2    23
                                                         p \< 0.01    10                         60          0         31     0    6
                                                         p \< 0.001   1                          5           0         3      0    1
                                                                                                                                   
  **14 months**                                                       **A[LL]{.smallcaps} FC**   **\>1.5**   **\>2**               
                                                                                                                                   
  **P[ROBE SETS THAT PASS SIGNAL FILTER]{.smallcaps}**                UP                         DOWN        UP        DOWN   UP   DOWN
  8200                                                   p \< 0.05    75                         614         7         120    2    22
                                                         p \< 0.01    10                         146         2         57     0    12
                                                         p \< 0.001   1                          22          0         9      0    2

Gene ontology analysis
----------------------

Gene ontology (GO) terms which were significantly enriched (at level p \< 0.05) amongst genes significantly differentially expressed between transgenic and wild type mice were identified for each time point. Over-represented GO terms at each time point are given in Tables [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}. Four GO clusters were identified: Ontology terms concerned with mitochondrial function and energy production, with steroid metabolism, with axonogenesis and nervous system development, and with gene expression and RNA metabolism. There is overlap between GO terms enriched at 3 months and 5 months, and between 5 months and late stage disease, suggesting that the processes represented by these terms are affected in transgenic mice in a sequential manner, as disease progresses.

###### 

GO terms significantly enriched amongst differentially expressed genes at 3 months

  Gene ontology term                                        No. of genes   Fold Enrichment   p value
  --------------------------------------------------------- -------------- ----------------- ---------
  **Energy production**                                                                      
  tricarboxylic acid cycle intermediate metabolic process   4              9.8               0.0066
  generation of precursor metabolites and energy            18             1.9               0.0128
  Carbohydrate metabolic process                            14             1.8               0.0454
                                                                                             
  **Other**                                                                                  
  cardiac muscle cell differentiation                       3              12.7              0.0212
  striated muscle cell differentiation                      4              6.2               0.0246
  cardiac cell differentiation                              3              9.8               0.0348
  response to temperature stimulus                          4              4.9               0.0454

###### 

GO terms significantly enriched amongst differentially expressed genes at 5 months

  Gene ontology term                                No. of genes   Fold Enrichment   p value
  ------------------------------------------------- -------------- ----------------- ---------
  **Nervous system development**                                                     
  axon extension                                    6              8.1               0.0006
  cell part morphogenesis                           18             2.4               0.0010
  cell projection organization and biogenesis       18             2.4               0.0010
  cell projection morphogenesis                     18             2.4               0.0010
  regulation of axon extension                      5              10.2              0.0010
  regulation of axonogenesis                        6              5.6               0.0035
  regulation of neurogenesis                        7              4.5               0.0040
  cellular morphogenesis during differentiation     13             2.5               0.0055
  positive regulation of cell adhesion              4              8.9               0.0087
  axonogenesis                                      11             2.6               0.0090
  neurite development                               13             2.3               0.0093
  nervous system development                        27             1.7               0.0105
  cell morphogenesis                                23             1.7               0.0135
  cellular structure morphogenesis                  23             1.7               0.0135
  neurite morphogenesis                             11             2.4               0.0175
  neuron morphogenesis during differentiation       11             2.4               0.0175
  neuron development                                13             2.1               0.0183
  microtubule-based process                         12             2.1               0.0249
  negative regulation of axon extension             3              10.5              0.0304
  neuron differentiation                            14             1.9               0.0346
  negative regulation of neurogenesis               4              5.4               0.0348
  Neurogenesis                                      16             1.7               0.0403
  cell migration                                    13             1.9               0.0413
  generation of neurons                             15             1.8               0.0457
  negative regulation of axonogenesis               3              8.1               0.0493
                                                                                     
  **Cholesterol metabolism**                                                         
  cholesterol metabolic process                     7              3.9               0.0083
  steroid biosynthetic process                      8              4.3               0.0021
  sterol biosynthetic process                       6              5.9               0.0030
  sterol metabolic process                          8              3.9               0.0039
  steroid metabolic process                         10             2.9               0.0064
  cholesterol biosynthetic process                  5              6.1               0.0078
                                                                                     
  **RNA metabolism**                                                                 
  nuclear mRNA splicing, via spliceosome            7              3.4               0.0153
  RNA splicing, via transesterification reactions   7              3.4               0.0153
                                                                                     
  **Energy production**                                                              
  generation of precursor metabolites and energy    20             1.7               0.0282
                                                                                     
  **Other**                                                                          
  protein import                                    8              3.3               0.0106
  leukocyte migration                               4              8.1               0.0112
  protein import into nucleus                       7              3.6               0.0115
  leukocyte migration                               4              8.1               0.0112
  protein import into nucleus                       7              3.6               0.0115
  nuclear import                                    7              3.5               0.0140
  nucleocytoplasmic transport                       9              2.5               0.0249
  feeding behaviour                                 4              6.1               0.0253
  nuclear transport                                 9              2.5               0.0265
  alcohol metabolic process                         14             1.9               0.0296

###### 

GO terms significantly enriched amongst differentially expressed genes at 14 months

  Gene ontology term                                                        No. of genes   Fold Enrichment   p value
  ------------------------------------------------------------------------- -------------- ----------------- ---------
  **RNA metabolism and regulation of gene expression**                                                       
  protein-RNA complex assembly                                              11             2.5               0.011
  mRNA metabolic process                                                    23             1.7               0.012
  mRNA processing                                                           21             1.8               0.014
  gene expression                                                           136            1.2               0.015
  RNA splicing                                                              18             1.8               0.018
  Regulation of gene expression                                             98             1.2               0.024
  Regulation of transcription                                               91             1.2               0.032
  regulation of nucleoside, nucleotide and nucleic acid metabolic process   92             1.2               0.040
  transcription                                                             93             1.2               0.047
  negative regulation of gene expression, epigenetic                        4              4.7               0.048
                                                                                                             
  **Nervous system development**                                                                             
  neurite morphogenesis                                                     14             2.0               0.018
  neuron morphogenesis during differentiation                               14             2.0               0.018
  axonogenesis                                                              13             2.1               0.019
  neurite development                                                       15             1.8               0.037
  cellular morphogenesis during differentiation                             14             1.8               0.040
  neuron development                                                        16             1.7               0.045
                                                                                                             
  **Other**                                                                                                  
  nuclear export                                                            8              4.6               0.001
  protein export from nucleus                                               5              6.9               0.004
  negative regulation of metabolic process                                  23             1.6               0.029
  phosphatidylinositol metabolic process                                    4              5.5               0.032
  nucleocytoplasmic transport                                               11             2.1               0.034
  macromolecule biosynthetic process                                        41             1.4               0.034
  nuclear transport                                                         11             2.1               0.036
  negative regulation of cellular metabolic process                         20             1.6               0.046
  phospholipid metabolic process                                            11             2.0               0.047
  heme metabolic process                                                    4              4.7               0.048

Mitochondrial function and energy production
--------------------------------------------

In presymptomatic mice, fewer transcriptional changes were seen in transgenic mice, compared to their wild-type littermates than at the other time points of disease. The most significantly over-represented GO terms related to cellular energy production (TCA cycle metabolism, generation of precursor metabolites and energy and carbohydrate metabolism). The differentially expressed genes included several genes encoding TCA cycle enzymes and components of the electron transport chain (Table [6](#T6){ref-type="table"}). Three genes encoding TCA cycle enzymes, *Mdh2*, *Ldh2*and *Oxct1*, are upregulated, while *Ldh1*, an isoform that favours glycolysis over oxidative metabolism \[[@B22]\], is downregulated. In the electron transport chain, genes that produce components of 4 out of the 5 complexes, and *Pcdc8*, which is required for mitochondrial oxidative phosphorylation \[[@B23]\], show upregulation (Figure [3](#F3){ref-type="fig"}). These gene expression changes would be consistent with a small but significant increase in oxidative metabolism in neurones of VEGF^δ/δ^mice in the early stages of disease. Concomitant with this increase, there was upregulation of the free radical scavenging enzymes, *Prdx2*and *Sod2*.

![**Diagrammatic representation of the components of the mitochondrial electron transport chain, and the constituent proteins encoded by genes significantly upregulated in VEGF^δ/δ^mice**.](1471-2164-11-203-3){#F3}

###### 

Differentially regulated genes involved in cellular energy production at 3 months

  Probe ID                       Gene title                                                                     Symbol   p value   FC     Regn
  ------------------------------ ------------------------------------------------------------------------------ -------- --------- ------ ------
  **Electron transport chain**                                                                                                            
  1438159                        NADH dehydrogenase (ubiquinone) flavoprotein 2                                 Ndufv2   0.0330    1.15   up
  1435757                        Ubiquinol cytochrome C reductase core protein 2                                Uqcrc2   0.0066    1.21   up
  1456588                        Cytochrome c oxidase, subunit Vb                                               Cox5b    0.0460    1.16   up
  1450561                        Surfeit gene 1                                                                 Surf1    0.0187    1.16   up
  1449710                        ATP synthase H+ transporting, mitochondrial F1 complex, α subunit, isoform 1   Atp5a1   0.0216    1.09   up
  1454661                        ATP synthase H+ transporting, mitochondrial F0 complex, subunit c, isoform 3   Atp5g3   0.0309    1.06   up
  1418127                        Programmed cell death 8 (Apoptosis inducing factor)                            Pcdc8    0.0185    1.26   up
                                                                                                                                          
  **TCA cycle**                                                                                                                           
  1419737                        Lactate dehydrogenase 1, A chain                                               Ldh1     0.0077    1.86   down
  1433984                        Malate dehydrogenase 2, NAD                                                    Mdh2     0.0188    1.16   up
  1455235                        Lactate dehydrogenase 2, B chain                                               Ldh2     0.0216    1.12   up
  1436750                        3-oxoacid CoA transferase1                                                     Oxct1    0.0441    1.30   up
                                                                                                                                          
  **Free radical scavenging**                                                                                                             
  1430979                        Peroxiredoxin 2                                                                Prdx2    0.0397    1.27   up
  1444531                        Superoxide dismutase 2, mitochondrial                                          Sod2     0.0417    1.20   up

Cholesterol metabolism
----------------------

At disease onset, there was enrichment of genes assigned GO terms relating to steroid metabolism, all of which were downregulated (Table [7](#T7){ref-type="table"}). These included five genes that catalyse reactions in the final committed pathway to cholesterol synthesis pathway (Figure [4](#F4){ref-type="fig"}). *Sqle*is a rate limiting step in this pathway \[[@B24]\]. *Prkaa2*is a catalytic subunit of AMPK, which regulates HMG CoA reductase activity. *Ldlr*and *Sorl1*have similar functions in binding LDL, the major cholesterol carrying lipoprotein of plasma, and transporting it into cells. *Hsd17b7*catalyses the synthesis of steroid hormones from cholesterol, while *Stard4*promotes transport of cholesterol across the mitochondrial membrane, and stimulates steroidogenesis \[[@B25]\]. *Nr3c1*is the glucocorticoid receptor.

![**Schematic representation of the cholesterol biosynthesis pathway, with genes that are differentially regulated in VEGF^δ/δ^mice at 5 months highlighted in red**. Cytochrome B5 reductase is an electron carrier for 5-desaturase and methyl sterol oxidase \[[@B119]\]](1471-2164-11-203-4){#F4}

###### 

Differentially expressed genes in the category of \'Steroid metabolism\' at 5 months

  Probe ID   Gene Title                                                Symbol    p value   FC     Regn
  ---------- --------------------------------------------------------- --------- --------- ------ ------
  1416222    NAD(P) dependent steroid dehydrogenase-like               Nsdhl     0.0372    1.77   down
  1421821    low density lipoprotein receptor                          Ldlr      0.0172    2.13   down
  1422185    cytochrome b5 reductase 3                                 Cyb5r3    0.0248    2.24   down
  1423078    sterol-C4-methyl oxidase-like                             Sc4mol    0.0161    2.10   down
  1429240    StAR-related lipid transfer (START) domain containing 4   Stard4    0.0044    1.83   down
  1438322    farnesyl diphosphate farnesyl transferase 1               Fdft1     0.0442    1.56   down
  1448130    farnesyl diphosphate farnesyl transferase 1               Fdft1     0.0323    1.86   down
  1457248    hydroxysteroid (17-beta) dehydrogenase 7                  Hsd17b7   0.0250    1.74   down
  1460390    sortilin-related receptor, LDLR class A                   Sorl1     0.0499    1.33   down
  1415993    squalene epoxidase                                        Sqle      0.0204    1.97   down

Nervous system development
--------------------------

At all stages of disease, there was differential expression of genes involved in nervous system development, with prominent enrichment of GO terms relating to nervous system development in the significant gene lists at both 5 months and 14 months. Genes with functions relating to nervous system development at these time points, the majority of which are downregulated, are shown in Table [8](#T8){ref-type="table"} and Figure [5](#F5){ref-type="fig"}. Several are identified by more than one probe set or at more than one time point.

![**Schematic representation of genes involved in neuronal migration, neurite outgrowth and formation and maintenance of the neuromuscular junction, which are all downregulated in the VEGF transgenic mouse**.](1471-2164-11-203-5){#F5}

###### 

Differentially expressed genes in the category of \'Nervous system development\'

  Probe ID                                Gene Title                                                             Symbol     p value   FC     Regn   Time point
  --------------------------------------- ---------------------------------------------------------------------- ---------- --------- ------ ------ ------------
  **Neurite outgrowth**                                                                                                                             
  1428393                                 neuritin 1                                                             Nrn1       0.0090    3.82   down   14 months
  1428089                                 SLIT and NTRK-like family, member 1                                    Slitrk1    0.0156    1.35   down   5 months
  1416666                                 serine peptidase inhibitor, clade E, member 2                          Serpine2   0.0414    1.65   down   5 months
  1437308                                 coagulation factor II (thrombin) receptor                              F2r        0.0346    1.59   up     3 months
  1437308                                 coagulation factor II (thrombin) receptor                              F2r        0.0286    1.22   up     5 months
  1455252                                 tuberous sclerosis 1                                                   Tsc1       0.0073    1.37   up     5 months
  1422600                                 RAS protein-specific guanine nucleotide-releasing factor 1             Rasgrf1    0.0011    1.63   down   14 months
  1435614                                 RAS protein-specific guanine nucleotide-releasing factor 1             Rasgrf1    0.0002    1.44   down   14 months
  1455027                                 RUN and FYVE domain containing 2                                       Rufy3      0.0360    1.43   down   5 months
  1424402                                 RUN and FYVE domain containing 2                                       Rufy3      0.0382    1.32   down   5 months
  1452342                                 amyloid beta precursor protein-binding, family B, member 2             Apbb2      0.0415    1.21   down   14 months
  1449439                                 Kruppel-like factor 7 (ubiquitous)                                     Klf7       0.0008    1.62   down   5 months
                                                                                                                                                    
  **Growth factor signalling pathways**                                                                                                             
  1420838                                 neurotrophic tyrosine kinase, receptor, type 2                         Ntrk2      0.0067    1.29   down   5 months
  1418057                                 T-cell lymphoma invasion and metastasis 1                              Tiam1      0.0006    1.66   down   5 months
  1418057                                 T-cell lymphoma invasion and metastasis 1                              Tiam1      0.0031    1.43   down   14 months
  1439015                                 glial cell line derived neurotrophic factor receptor alpha 1           Gfra1      0.0454    1.95   down   5 months
  1455018                                 lemur tyrosine kinase 2                                                Lmtk2      0.0107    1.32   down   14 months
                                                                                                                                                    
  **TGFß signalling pathway**                                                                                                                       
  1450923                                 transforming growth factor, beta 2                                     Tgfb2      0.0397    1.47   down   5 months
  1450839                                 DNA segment, human D4S114                                              D0H4S114   0.0093    2.00   down   3 months
  1450839                                 DNA segment, human D4S114                                              D0H4S114   0.0190    1.98   down   5 months
  1450839                                 DNA segment, human D4S114                                              D0H4S114   0.0025    1.50   down   14 months
  1422487                                 MAD homolog 4 (Drosophila)                                             Smad4      0.0368    1.41   down   5 months
  1452143                                 spectrin beta 2                                                        Spnb2      0.0023    1.21   down   5 months
  1425116                                 spectrin beta 4                                                        Spnb4      0.0463    1.14   up     14 months
                                                                                                                                                    
  **Rho-GTPase pathway**                                                                                                                            
  1416329                                 cytoplasmic FMR1 interacting protein 1                                 Cyfip1     0.0158    1.36   down   5 months
  1448600                                 vav 3 oncogene                                                         Vav3       0.0304    1.32   down   5 months
                                                                                                                                                    
  **Microtubule-based processes**                                                                                                                   
  1455719                                 tubulin, beta 5                                                        Tubb5      0.0034    1.60   down   5 months
  1421851                                 microtubule-associated protein 1 B                                     Mtap1b     0.0142    2.10   down   5 months
  1457316                                 microtubule-associated protein 6                                       Mtap6      0.0105    1.75   down   5 months
  1424719                                 microtubule-associated protein tau                                     Mapt       0.0482    1.50   down   5 months
  1417005                                 kinesin 2                                                              Kns2       0.0484    1.17   down   5 months
  1433926                                 dynein, cytoplasmic, light intermediate chain 2                        Dnclic2    0.0121    1.36   down   5 months
  1437875                                 bicaudal D homolog 2                                                   Bicd2      0.0236    1.45   down   5 months
  1451630                                 tubulin tyrosine ligase                                                Ttl        0.0016    1.45   down   5 months
  1428282                                 tubulin-specific chaperone e                                           Tbce       0.0348    1.24   down   14 months
  1423626                                 dystonin                                                               Dst        0.0358    1.24   down   5 months
                                                                                                                                                    
  **Axon guidance**                                                                                                                                 
  1418084                                 neuropilin 1                                                           Nrp1       0.0092    2.02   down   5 months
  1448944                                 neuropilin 1                                                           Nrp1       0.0151    1.58   down   5 months
  1456778                                 neuropilin 2                                                           Nrp2       0.0020    1.28   down   5 months
  1420416                                 semaphorin 3A                                                          Sema3a     0.0010    1.35   down   5 months
  1420416                                 semaphorin 3A                                                          Sema3a     0.0341    1.26   down   14 months
  1415877                                 dihydropyrimidinase-like 3                                             Dpysl3     0.0461    2.25   down   5 months
  1450863                                 double cortin and calcium/calmodulin-dependent protein kinase-like 1   Dcamkl1    0.0364    1.29   down   5 months
                                                                                                                                                    
  **Synapse formation and plasticity**                                                                                                              
  1427898                                 ring finger protein (C3H2C3 type) 6                                    Rnf6       0.0182    1.59   down   5 months
  1452004                                 calcitonin-related polypeptide, alpha                                  Calca      0.0283    1.26   down   5 months
  1422639                                 calcitonin-related polypeptide, beta                                   Calcb      0.0389    1.78   down   5 months
  1449465                                 reelin                                                                 Reln       0.0006    2.38   down   3 months
  1423100                                 FBJ osteosarcoma oncogene                                              Fos        0.0313    2.32   down   3 months
  1423100                                 FBJ osteosarcoma oncogene                                              Fos        0.0123    2.17   down   5 months
  1452901                                 cAMP responsive element binding protein 1                              Creb1      0.0148    1.44   down   14 months
                                                                                                                                                    
  **Wingless signalling pathway**                                                                                                                   
  1437301                                 dishevelled, dsh homolog 1 (Drosophila)                                Dvl1       0.0166    1.38   down   14 months
  1434439                                 glycogen synthase kinase 3 beta                                        Gsk3b      0.0023    1.23   down   14 months
  1437351                                 CXXC finger 4                                                          Cxxc4      0.0462    1.37   down   5 months
  1437351                                 CXXC finger 4                                                          Cxxc4      0.0341    1.30   down   14 months
                                                                                                                                                    
  **Cell adhesion molecules**                                                                                                                       
  1437466                                 activated leukocyte cell adhesion molecule                             Alcam      0.0329    1.94   down   5 months
  1437467                                 activated leukocyte cell adhesion molecule                             Alcam      0.0233    1.60   down   5 months
  1437466                                 activated leukocyte cell adhesion molecule                             Alcam      0.0400    1.65   down   14 months
  1426301                                 activated leukocyte cell adhesion molecule                             Alcam      0.0045    1.51   down   14 months
  1437467                                 activated leukocyte cell adhesion molecule                             Alcam      0.0414    1.50   down   14 months
  1416034                                 CD24a antigen                                                          Cd24a      0.0165    1.96   down   5 months
  1416891                                 numb gene homolog (Drosophila)                                         Numb       0.0394    1.45   down   14 months
  1424954                                 phosphatidylinositol-4-phosphate 5-kinase, type 1 gamma                Pip5k1c    0.0166    1.14   down   14 months
  1418615                                 astrotactin 1                                                          Astn1      0.0461    1.65   down   5 months
  1416474                                 immunoglobulin superfamily, DCC subclass, member 4                     Igdcc4     0.0342    1.19   down   5 months
  1449286                                 netrin G1                                                              Ntng1      0.0119    1.87   down   14 months
  1442659                                 protocadherin 9                                                        Pcdh9      0.0166    1.64   down   14 months
  1420429                                 protocadherin beta 3                                                   Pcdhb3     0.0365    1.89   down   14 months
  1425092                                 cadherin 10                                                            Cdh10      0.0208    1.39   down   14 months
  1433788                                 neurexin III                                                           Nrxn3      0.0021    1.78   down   14 months
  1422798                                 contactin associated protein-like 2                                    Cntnap2    0.0077    1.37   down   5 months
  1417378                                 synaptic cell adhesion molecule                                        Syncam     0.0400    1.40   down   14 months
  1417377                                 synaptic cell adhesion molecule                                        Syncam     0.0191    1.38   down   14 months
  1422445                                 integrin alpha 6                                                       Itga6      0.0221    1.50   down   5 months
                                                                                                                                                    
  **Others**                                                                                                                                        
  1457015                                 Neurofilament 3, medium                                                Nef3       0.0209    1.40   up     14 months
  1416533                                 EGL nine homolog 2                                                     Egln2      0.0203    1.46   down   5 months
  1420475                                 myotrophin                                                             Mtpn       0.0120    1.67   down   5 months
  1417133                                 peripheral myelin protein                                              Pmp22      0.0159    1.89   down   5 months
  1449353                                 wild-type p53-induced gene 1                                           Wig1       0.0249    1.57   down   5 months
  1417624                                 Ngfi-A binding protein 1                                               Nab1       0.0119    1.44   down   5 months

There is downregulation in VEGF^δ/δ^mice of genes that promote neurite outgrowth, such as *Nrn1*\[[@B26]\], *Slitrk1*\[[@B27]\], *RasGrf1*\[[@B28]\] and *Serpine2*, which is an inhibitor of thrombin \[[@B29]\]. Thrombin causes neurite retraction and neuronal death via its receptor *F2r*, which is upregulated at 3 and 5 months \[[@B30]\]. *Tsc1*, which inhibits axon growth, is also upregulated at both time points \[[@B31]\]. Growth factors such and NGF, BDNF, GDNF and TGFß2 promote neuronal differentiation and outgrowth \[[@B32],[@B33]\], There is downregulation in motor neurones of VEGF^δ/δ^mice of the BDNF receptor, *Ntrk2*, and its downstream mediator, *Tiam1*\[[@B34]\]; the GDNF receptor, *Gfra1*; several components of the TGFß2 signaling pathway; and *Lmtk2*, a mediator of NGF signalling \[[@B35]\]. *Rufy3*is implicated in the formation of a single axon, to determine neuronal polarity \[[@B36]\]. *Apbb2*interacts with amyloid precursor protein, which is required for the maintenance of dendrites and synapses \[[@B37]\]. *KLF7*is a transcription factor with a key role in neuronal morphogenesis. Null mutations in Klf7 lead to deficits in neuronal outgrowth and axon guidance \[[@B38]\]. The Rho GTPase pathway controls cytoskeletal reorganization to regulate neurone outgrowth, and the maturation and maintenance of dendritic spines. The Rho GTPase, Rac, is activated by *vav3*\[[@B39]\]. *Cyfip1*interacts with Rac and null mutations lead to defects in axon growth, guidance and branching, and in the organization of the neuromuscular junction \[[@B40]\].

The GO category \'microtubule-based process\' is over-represented at 5 months, with downregulation of genes that are assigned this function. Microtubules are prominent elements of the neuronal cytoskeleton, involved in the growth and maintenance of neurites, and along which motor proteins move. Microtubule associated proteins bind to the tubulin substrate that make up microtubules, and regulate their stability \[[@B41]\]. Tubulin ß5 and three microtubule associated proteins, *Maptau*, *Mtap1b*and *Mtap6*, are downregulated in VEGF^δ/δ^mice, as are two motor proteins, *kinesin 2*and *Dnclic2*, and *BICD2*which binds cargoes to dynein. Disruption of the dynein-dynactin pathway through prevention of BICD2 uncoupling causes motor neurone degeneration in mice \[[@B42]\]. *Ttl*causes post-translational modifications of αtubulin that are essential to neurite extension and normal brain development \[[@B43]\]. *Tbce*is a tubulin chaperone, required for stabilization of neuronal processes, a mutation of which causes the progressive motor neuronopathy of the *pmn*mouse \[[@B44]\]. *Dystonin*is thought to have a role in cytoskeletal cross-linking leading to axonal stability \[[@B45]\].

Differentially expressed genes in the VEGF^δ/δ^model encode a number of proteins that mediate attractive and repulsive growth cone signals during axonal guidance, including *Nrp1*and its ligand *sema3A*\[[@B46]\] and *Nrp2*\[[@B47]\]. Two downregulated genes have regulatory functions in the growth cone tip: *Dpysl3*and *DCAMKII*\[[@B48],[@B49]\].

Cellular adhesion molecules are important in contact-dependent regulation of axonal growth, and in the control of neuronal migration. Fourteen adhesion molecules and related molecules are downregulated in the VEGF^δ/δ^mouse. *Alcam*is a member of the immunoglobulin superfamily which has a specific role in the guidance of motor axons and formation of neuromuscular junctions (NMJs) \[[@B50]\]. Both L1 and cd24 interact and cooperate with each other as potent stimulators of neurite outgrowth \[[@B51]\]. *Cd24*, and *Numb*, which mediates endocytosis of the cell-adhesion molecule L1 \[[@B52]\] are downregulated in VEGF^δ/δ^mice. The DCC (deleted in colon cancer) subgroup of the immunoglobulin superfamily are ligands for netrin, with roles in the migration and guidance of axonal growth cones. *Igdcc4*is a newly recognized member of this group, which is downregulated at 5 months \[[@B53]\], as is the netrin *Ntng1*\[[@B54]\]. Both *Pip5k1c*and *Astn1*are required for normal neurone migration \[[@B55],[@B56]\].

The formation of synapses involves guidance of axonal processes towards target cells, target recognition, followed by recruitment of pre- and post-synaptic elements. The synaptic connections between motor neurones and muscle exhibit both functional and anatomical plasticity after maturation, with changes in synaptic strength, and the formation and retraction of neuronal sprouts from synaptic terminals or Nodes of Ranvier. This enables the neuromuscular system to compensate for growth, changes in muscle use, and damage or disease \[[@B57]\]. Adhesion molecules play a central role in the formation and plasticity of synapses, several of which are downregulated in the VEGF^δ/δ^mouse, including two protocadherins; cadherin 10 \[[@B58],[@B59]\]; two members of the neurexin family, *Nrxn3*and *Cntnap2*, which bind postsynaptic neuroligins \[[@B60],[@B61]\]; and *SynCAM*, a member of the immunoglobulin superfamily. *Rnf6*binds to LIM kinase 1, which regulates actin dynamics and is important in determining synaptic structure \[[@B62]\]. Calcitonin-gene-related peptide, of which both polypeptide chains are downregulated in the VEGF^δ/δ^mouse, is released from motor neurones to stimulate acetylcholine receptor synthesis by muscle, at the NMJ \[[@B63]\]. Reelin is an extracellular matrix protein with a well-recognized function in neuronal migration. More recently, it has been shown to play a role in synaptic plasticity \[[@B64]\], and in the maturation of synaptic contacts during development, by refinement of NMDA-receptor subunit composition \[[@B65]\]. The activation of downstream signalling pathways of reelin is cholesterol-dependent \[[@B66]\]. Fos and Jun form the heterodimer, AP-1, which plays a central role in controlling development, growth, survival and plasticity of neurones. AP-1 has also been shown to positively regulate synapse strength and number, acting upstream of CREB \[[@B67]\]. Both Fos and CREB are downregulated in the VEGF^δ/δ^mouse.

Proteins of the canonical wingless signalling pathway participate in the assembly of the NMJ, with crucial components being the wingless co-receptor, arrow, Dishevelled and GSK3ß. GSK3ß functions by regulating the structure of the microtubule cytoskeleton, probably via the microtubule-associated protein, MAP1B. Mutations in this pathway cause aberrant NMJ formation, with reduction in number of synaptic boutons \[[@B68]\]. *Dishevelled*, *GSK3ß*and *MAP1B*are downregulated in the VEGF^δ/δ^model, as is C*XXC4*which regulates the wnt-dishevelled signalling pathway \[[@B69]\]. TGFß also plays role in the development and functioning of synapses \[[@B70]\]. There is downregulation in the VEGF^δ/δ^mouse of TGFß2; D0H4S114, which regulates TGF signalling \[[@B71]\]; Smad4 and ß-spectrin at disease onset, which associate in response to TGFß, and are required for the assembly of the NMJ \[[@B72],[@B73]\].

Pre-synaptic proteins
---------------------

Concomitant with the downregulation of genes involved in the formation and morphological plasticity of synapses, a reduction was seen in the expression of several genes encoding proteins that comprise the pre-synaptic machinery (Table [9](#T9){ref-type="table"}), including several genes involved in the fusion of synaptic vesicles, which is mediated by the SNARE complex of VAMP/synaptobrevin, syntaxin and SNAP25. Both *VAMP3*and *Nap*b were downregulated in VEGF^δ/δ^mice, as was the syntaxin-binding protein, *Stxbp6*; *SytI1*, one of a family of calcium-binding proteins that need to be bound to the SNARE complex for pore opening to occur; the SNAP associated protein, *Snapap*, which enhances association of synaptotagmin with the SNARE complex \[[@B74]\]; *Unc13C*which binds to and activates syntaxin \[[@B75]\]; *gelsolin*which disassembles the actin network to liberate synaptic vesicles for release \[[@B76]\]; *piccolo*, which is a scaffolding protein involved in the organization of synaptic active zones, where synaptic vesicles dock and fuse \[[@B77]\]; and synapsins I and II, which modulate neurotransmitter release, possibly by maintaining a pool of synaptic vesicles near to the active zone \[[@B78]\]. PPI controls activity of ion channels and signal transduction enzymes to determine functional synaptic plasticity, and downregulation of several of its regulatory and catalytic subunits was seen, in addition to *Phactr1*and *2*, which regulate PPI activity \[[@B79]\].

###### 

Genes encoding presynaptic proteins, differentially expressed in VEGF^δ/δ^mice

  Probe ID   Gene name                                         Symbol     p value   FC     Reg    Time point
  ---------- ------------------------------------------------- ---------- --------- ------ ------ ------------
  1456245    vesicle-associated membrane protein 3             Vamp3      0.0159    1.47   down   14 months
  1423173    N-ethylmaleimide sensitive fusion protein ß       Napb       0.0021    1.59   down   14 months
  1423172    N-ethylmaleimide sensitive fusion protein ß       Napb       0.0024    1.55   down   14 months
  1433788    N-ethylmaleimide sensitive fusion protein ß       Napb       0.0021    1.78   down   14 months
  1435396    syntaxin binding protein 6                        Stxbp6     0.0290    1.46   down   5 months
  1435396    syntaxin binding protein 6                        Stxbp6     0.0179    1.33   down   14 months
  1429314    synaptotagmin XI                                  Syt11      0.0274    1.47   down   5 months
  1415756    SNAP-associated protein                           Snapap     0.0058    1.70   down   5 months
  1455304    unc-13 homolog C                                  Unc13c     0.0070    2.86   down   14 months
  1436991    gelsolin                                          Gsn        0.0092    1.62   down   5 months
  1419392    piccolo                                           Pclo       0.0267    1.47   down   14 months
  1451484    synapsin I                                        Syn1       0.0098    1.49   down   5 months
  1435511    synapsin II                                       Syn2       0.0146    1.74   down   5 months
  1435667    regulating synaptic membrane exocytosis 1         Rims1      0.0370    1.32   up     3 months
  1422880    synaptophysin-like protein                        Sypl       0.0384    1.15   down   3 months
  1417919    protein phosphatase 1, regulatory subunit 7       Ppp1r7     0.0256    1.30   down   5 months
  1433691    protein phosphatase 1, regulatory subunit 3C      Ppp1r3c    0.0218    1.49   down   5 months
  1440285    protein phosphatase 1, regulatory subunit 9A      Ppp1r9a    0.0063    1.24   down   5 months
  1452046    protein phosphatase 1, catalytic subunit, gamma   Ppp1cc     0.0276    1.38   down   5 months
  1434895    protein phosphatase 1, regulatory subunit 13B     Ppp1r13b   0.0280    1.32   down   14 months
  1456072    protein phosphatase 1, regulatory subunit 9A      Ppp1r9a    0.0217    1.32   down   14 months
  1440285    protein phosphatase 1, regulatory subunit 9A      Ppp1r9a    0.0304    1.22   down   14 months
  1420734    protein phosphatase 1, regulatory subunit 3F      Ppp1r3f    0.0102    1.17   down   14 months
  1456606    phosphatase and actin regulator 1                 Phactr1    0.0196    1.35   down   5 months
  1455101    phosphatase and actin regulator 2                 Phactr2    0.0489    1.66   down   5 months
  1455101    phosphatase and actin regulator 2                 Phactr2    0.0463    1.41   down   14 months

RNA processing
--------------

At late stage disease, GO terms related to gene expression and its regulation are enriched amongst significantly differentially expressed genes, including the sub-categories of mRNA metabolism and processing, and RNA splicing (Table [10](#T10){ref-type="table"}). Of the 651 named genes differentially expressed at 14 months, 143 (22%) have functions relating to gene expression, and of these, 132 (92%) are downregulated. This finding is interesting in light of the massive transcriptional downregulation seen at late stage disease.

###### 

Differentially expressed genes in the category \'Gene expression\'

  Probe ID   Gene Title                                                           Symbol      p value   FC     Regn
  ---------- -------------------------------------------------------------------- ----------- --------- ------ ------
  1437984    HLA-B-associated transcript 1A                                       Bat1a       0.0101    1.18   down
  1436549    heterogeneous nuclear ribonucleoprotein A1                           Hnrpa1      0.0354    1.30   down
  1452712    heterogeneous nuclear ribonucleoprotein A3                           Hnrpa3      0.0176    1.47   down
  1423873    LSM1 homolog, U6 small nuclear RNA associated                        Lsm1        0.0450    1.19   down
  1434704    myeloid/lymphoid or mixed-lineage leukaemia 5                        Mll5        0.0024    1.66   down
  1424136    peptidyl prolyl isomerase H                                          Ppih        0.0123    1.40   down
  1451909    PRP4 pre-mRNA processing factor 4 homolog B                          Prpf4b      0.0366    1.38   down
  1438420    RNA-binding region (RNP1, RRM) containing 2                          Rnpc2       0.0004    1.76   down
  1459765    splicing factor 1                                                    Sf1         0.0405    1.34   down
  1436898    splicing factor proline/glutamine rich                               Sfpq        0.0101    1.88   down
  1416151    splicing factor, arginine/serine-rich 3                              Sfrs3       0.0305    1.24   down
  1423130    splicing factor, arginine/serine-rich 5                              Sfrs5       0.0494    1.59   down
  1416721    splicing factor, arginine/serine-rich 6                              Sfrs6       0.0232    1.26   down
  1424033    splicing factor, arginine/serine-rich 7                              Sfrs7       0.0264    1.30   down
  1437180    small nuclear ribonucleoprotein 48                                   Snrnp48     0.0285    1.68   down
  1437007    ubiquitin specific peptidase 39                                      Usp39       0.0047    1.33   down
  1450845    basic leucine zipper and W2 domains 1                                Bzw1        0.0269    1.27   up
  1437841    cold shock domain containing C2, RNA binding                         Csdc2       0.0130    1.43   up
  1415920    cleavage stimulation factor, 3\' pre-RNA subunit 2, tau              Cstf2t      0.0092    1.27   down
  1437071    eukaryotic translation initiation factor 1A, Y-linked                Eif1ay      0.0281    1.21   down
  1434538    eukaryotic translation initiation factor 2B, subunit 2 beta          Eif2b2      0.0149    1.23   down
  1454664    eukaryotic translation initiation factor 5                           Eif5        0.0439    1.12   down
  1424252    heterogeneous nuclear ribonucleoprotein D-like                       Hnrpdl      0.0046    2.20   down
  1415911    imprinted and ancient                                                Impact      0.0009    1.47   down
  1451125    poly(A) binding protein interacting protein 2B                       Paip2b      0.0327    1.14   down
  1424216    poly (A) polymerase alpha                                            Papola      0.0286    1.55   down
  1427544    poly (A) polymerase alpha                                            Papola      0.0305    1.22   down
  1436586    ribosomal protein S14                                                Rps14       0.0321    1.25   down
  1416065    ankyrin repeat domain 10                                             Ankrd10     0.0494    1.27   down
  1435307    ankyrin repeat domain 34B                                            Ankrd34B    0.0154    5.84   down
  1452342    amyloid beta (A4) precursor protein-binding, family B, member 2      Apbb2       0.0415    1.21   down
  1455647    androgen receptor                                                    Ar          0.0248    1.30   down
  1420985    ash1 (absent, small, or homeotic)-like                               Ash1l       0.0413    1.23   down
  1450072    ash1 (absent, small, or homeotic)-like                               Ash1l       0.0416    1.22   down
  1449947    AT motif binding factor 1                                            Atbf1       0.0213    1.49   down
  1438992    activating transcription factor 4                                    Atf4        0.0069    1.35   down
  1418271    basic helix-loop-helix domain containing, class B5                   Bhlhb5      0.0456    1.69   down
  1452850    breast cancer metastasis-suppressor 1-like                           Brms1l      0.0371    1.28   down
  1435445    cyclin T2                                                            Ccnt2       0.0159    1.52   down
  1420497    CCAAT/enhancer binding protein zeta                                  Cebpz       0.0435    1.28   down
  1454641    CGG triplet repeat binding protein 1                                 Cggbp1      0.0063    1.42   down
  1434002    checkpoint supressor 1                                               Ches1       0.0452    1.37   down
  1438255    checkpoint supressor 1                                               Ches1       0.0459    1.41   down
  1436980    CCR4-NOT transcription complex, subunit 2                            Cnot2       0.0089    1.36   down
  1456576    CCR4-NOT transcription complex, subunit 2                            Cnot2       0.0046    1.31   down
  1437982    COX15 homolog, cytochrome c oxidase assembly protein                 Cox15       0.0406    1.14   up
  1452901    cAMP responsive element binding protein 1                            Creb1       0.0148    1.44   down
  1436983    CREB binding protein                                                 Crebbp      0.0428    1.23   down
  1452857    CREB/ATF bZIP transcription factor                                   Crebzf      0.0245    1.45   down
  1454931    CREBBP/EP300 inhibitory protein 2                                    Cri2        0.0384    1.24   down
  1429618    cylindromatosis (turban tumor syndrome)                              Cyld        0.0025    1.55   down
  1448234    DnaJ (Hsp40) homolog, subfamily B, member 6                          Dnajb6      0.0214    1.23   down
  1459805    dihydrouridine synthase 3-like                                       Dus3l       0.0103    1.39   down
  1418850    enhancer of polycomb homolog 1                                       Epc1        0.0133    1.23   down
  1455267    estrogen-related receptor gamma                                      Esrrg       0.0026    1.50   down
  1456615    fetal Alzheimer antigen                                              Falz        0.0130    1.33   down
  1423709    phenylalanine-tRNA synthetase-like, beta subunit                     Farslb      0.0270    1.34   down
  1459861    F-box and leucine-rich repeat protein 10                             Fbxl10      0.0052    1.32   down
  1428890    fem-1 homolog c                                                      Fem1c       0.0498    1.22   down
  1417113    germ cell-less homolog                                               Gcl         0.0341    1.31   down
  1424296    glutamate-cysteine ligase, catalytic subunit                         Gclc        0.0143    1.38   down
  1448381    G elongation factor 1                                                Gfm1        0.0045    1.35   down
  1437163    general transcription factor II H, polypeptide 4                     Gtf2h4      0.0446    1.17   up
  1425628    transcription factor TFII-I-alpha                                    Gtf2i       0.0296    1.32   down
  1416176    high mobility group box 1                                            Hmgb1       0.0077    1.29   down
  1455626    homeo box A9                                                         Hoxa9       0.0190    1.61   down
  1454760    HIV TAT specific factor 1                                            Htatsf1     0.0337    1.28   down
  1460669    interleukin enhancer binding factor 3                                Ilf3        0.0213    1.27   down
  1455762    kinase D-interacting substrate 220                                   Kidins220   0.0152    1.26   down
  1456341    Kruppel-like factor 9                                                Klf9        0.0080    1.38   down
  1455214    microphthalmia-associated transcription factor                       Mitf        0.0081    1.30   down
  1435547    MKL/myocardin-like 2                                                 Mkl2        0.0335    1.35   down
  1443500    myeloid/lymphoid or mixed lineage-leukemia translocation to 10       Mllt10      0.0080    1.16   up
  1457632    myeloid ecotropic viral integration site-related gene 1              Mrg1        0.0333    2.40   down
  1424204    mitochondrial ribosomal protein L13                                  Mrpl13      0.0101    1.24   down
  1434971    mitochondrial ribosomal protein L15                                  Mrpl15      0.0463    1.13   down
  1440989    mitochondrial ribosomal protein L35                                  Mrpl15      0.0041    1.35   down
  1456109    mitochondrial ribosomal protein S15                                  Mrps15      0.0311    1.30   down
  1452608    c-myc binding protein                                                Mycbp       0.0004    1.47   down
  1423201    nuclear receptor co-repressor 1                                      Ncor1       0.0107    1.26   down
  1447693    Neogenin                                                             Neo1        0.0410    1.18   down
  1448963    nuclear transcription factor-Y gamma                                 Nfyc        0.0215    1.19   down
  1434398    NF-kappaB repressing factor                                          Nkrf        0.0074    1.71   down
  1419112    nemo like kinase                                                     Nlk         0.0478    1.27   down
  1416958    nuclear receptor subfamily 1, group D, member 2                      Nr1d2       0.0079    1.57   down
  1454851    nuclear receptor subfamily 2, group C, member 2                      Nr2c2       0.0491    1.15   down
  1448493    polyadenylate-binding protein-interacting protein 2                  Paip2       0.0261    1.42   down
  1426878    polybromo1                                                           Pbrm1       0.0033    1.22   down
  1427266    polybromo1                                                           Pbrm1       0.0046    1.31   down
  1417493    polycomb group ring finger 4                                         Pcgf4       0.0091    1.24   down
  1453271    PHD finger protein 14                                                Phf14       0.0151    1.52   down
  1456395    peroxisome proliferative activated receptor, γ, coactivator 1a       Ppargc1a    0.0001    1.66   down
  1456037    prolactin regulatory element binding                                 Preb        0.0147    1.41   down
  1428254    purine rich element binding protein B                                Purb        0.0102    1.29   down
  1436979    RNA binding motif protein 14                                         Rbm14       0.0106    1.19   down
  1422660    RNA binding motif protein 3                                          Rbm3        0.0398    1.54   up
  1443922    REST corepressor 3 (Rcor3), mRNA                                     Rcor3       0.0495    1.32   up
  1434521    regulatory factor X domain containing 2 homolog                      Rfxdc2      0.0103    1.39   down
  1438505    ribonuclease III, nuclear                                            Rnasen      0.0341    1.14   down
  1426660    ribosomal protein L23a                                               Rpl23a      0.0332    1.26   down
  1437975    ribosomal protein L23a                                               Rpl23a      0.0488    1.18   down
  1436046    ribosomal protein L29                                                Rpl29       0.0144    1.15   down
  1448846    ribosomal protein L29                                                Rpl29       0.0314    1.20   down
  1454627    ribosomal protein L29                                                Rpl29       0.0113    1.38   down
  1455348    ribosomal protein L29                                                Rpl29       0.0203    1.21   down
  1420381    ribosomal protein L31                                                Rpl31       0.0134    1.40   down
  1438986    ribosomal protein S17                                                Rps17       0.0496    1.24   down
  1430288    ribosomal protein S21                                                Rps21       0.0471    1.19   down
  1415876    ribosomal protein S26                                                Rps26       0.0311    1.33   down
  1423763    ribosomal protein S28                                                Rps28       0.0406    1.15   down
  1435816    ribosomal protein S6                                                 Rps6        0.0011    1.15   up
  1448584    arginine/serine-rich coiled-coil 1                                   Rsrc1       0.0148    1.25   down
  1428219    RING1 and YY1 binding protein                                        Rybp        0.0223    1.46   down
  1416008    special AT-rich sequence binding protein 1                           Satb1       0.0242    1.28   down
  1417892    sirtuin 3 (silent mating type information regulation 2, homolog) 3   Sirt3       0.0200    1.27   down
  1426668    solute carrier family 30 (zinc transporter), member 9                Slc30a9     0.0325    1.34   down
  1429624    SAFB-like transcription modulator                                    Sltm        0.0193    1.21   down
  1436703    small nuclear RNA activating complex, polypeptide 2                  Snapc2      0.0432    1.14   up
  1444531    Superoxide dismutase 2, mitochondrial                                Sod2        0.0254    1.21   up
  1451542    single-stranded DNA binding protein 2                                Ssbp2       0.0262    1.40   down
  1434238    RNA polymerase II, TATA box binding protein-associated factor        Taf2        0.0063    1.54   down
  1436318    TAR DNA binding protein                                              Tardbp      0.0104    1.60   down
  1452593    transcription elongation factor B (SIII), polypeptide 1              Tceb1       0.0360    1.15   up
  1421147    telomeric repeat binding factor 2                                    Terf2       0.0355    1.24   down
  1460545    thyroid hormone receptor associated protein 3                        Thrap3      0.0201    1.11   down
  1416812    cytotoxic granule-associated RNA binding protein 1                   Tia1        0.0287    1.47   down
  1416814    cytotoxic granule-associated RNA binding protein 1                   Tia1        0.0115    1.50   down
  1434898    trinucleotide repeat containing 6a                                   Tnrc6a      0.0004    1.57   down
  1434899    trinucleotide repeat containing 6a                                   Tnrc6a      0.0039    1.43   down
  1438376    tripartite motif protein 27                                          Trim27      0.0415    1.15   down
  1426954    tripartite motif protein 33                                          Trim33      0.0320    1.27   down
  1447780    Tu translation elongation factor, mitochondrial                      Tufm        0.0433    1.16   down
  1435389    ubiquitin A-52 residue ribosomal protein fusion product 1            Uba52       0.0105    1.35   down
  1455222    upstream binding protein 1                                           Ubp1        0.0403    1.35   down
  1427097    WW domain containing E3 ubiquitin protein ligase 1                   Wwp1        0.0464    1.25   down
  1420011    X-box binding protein 1                                              Xbp1        0.0167    1.24   down
  1437223    X-box binding protein 1                                              Xbp1        0.0496    1.33   down
  1422569    YY1 transcription factor                                             Yy1         0.0313    1.35   down
  1457285    zinc finger protein 187                                              Zfp187      0.0332    1.20   down
  1426895    zinc finger protein 191                                              Zfp191      0.0081    1.18   down
  1456824    zinc finger protein 612                                              Zfp612      0.0388    1.16   down
  1437873    zinc finger protein 799                                              Zfp799      0.0078    1.48   down
  1448875    zinc fingers and homeoboxes protein 1                                Zhx1        0.0471    1.18   down
  1426531    zinc finger, MYND domain containing 11                               Zmynd11     0.0005    1.32   down

Among the changes seen in this functionally category of genes, was downregulation of a number of splicing factors, and other genes involved in mRNA processing. Several ribosomal components also showed reduced expression. The cAMP responsive element binding protein, *CREB1*is a stimulus-inducible transcription factor which mediates nuclear responses underlying the development, function and plasticity of the nervous system \[[@B80]\]. Downregulation of several members of the CREB family is seen in VEGF^δ/δ^mice-*CREB1*, *CREBBP*, *CREBzf*, its interacting partner, *ATF4*(*CREB2*), and *Cri2*. Inactivation of neuronal CREB1 has been shown to cause defects in neurone migration, similar to those observed with reelin \[[@B81]\], and to stimulate neurodegeneration \[[@B82]\]. There is also downregulation of the androgen receptor, and related nuclear receptors, *Nr1d2*, *Nr2c2*and the oestrogen receptor, *Esrrg*. Steroid hormones have wide ranging effects on the structure and function of the nervous system. Androgen receptor function is known to be important for motor neurone survival, and disruption of this function in Kennedy\'s disease contributes to the motor neurone degeneration seen in this condition \[[@B83]\].

Verification of microarray results by QPCR
------------------------------------------

The results of QPCR verification for the 15 representative genes chosen is shown in Table [11](#T11){ref-type="table"}. Eight genes showed a significant downregulation of expression in VEGF^δ/δ^mice, which supported the microarray findings. A further 4 showed a trend towards downregulation which failed to reach significance, while 4 showed no change in expression despite a finding of significant expression by microarray analysis. The majority of microarray publications have indicated that arrays and QPCR analysis usually support each other qualitatively. However, it is well recognized that significant quantitative differences occur between microarray and QPCR data \[[@B84]\]. This may be related to gene specific variation in the hybridization kinetics associated with the two technologies, low fold changes or hybridization signals in the microarray experiment, or lack of transcript concordance between the probes used for microarray and QPCR analysis. The proportion of genes validated by this study using QPCR, with the larger sample sizes at 3 and 5 months, is comparable to that found by other studies \[[@B85],[@B86]\]. Although not all changes seen on microarray were validated by QPCR, it has been argued that where the focus of microarray analysis is the overall pattern of gene expression rather than the response of a few genes, as in this study, there is less utility in confirming the expression differences of individual genes \[[@B87]\].

###### 

Comparison of QPCR and microarray data of the 15 genes selected for verification

                                     Microarray result   QPCR result                           
  ---------------- ----------------- ------------------- ----------------- ------- ----------- -------------
  **Time point**   **Gene Symbol**   **FC**              **P value**       **n**   **FC**      **P value**
                                                                                               
  **3 months**     Zfp101            +4.35               0.01              6       No change   
                   **Fos**           -2.32               0.03              6       **-2.59**   **0.0003**
                   **Reelin**        -1.88               0.004             6       **-1.68**   **0.03**
                   HspA5             -1.44 to -1.46      0.02 to 0.01      6       -1.34       0.06
                                                                                               
  **5 months**     **Fos**           -2.17               0.01              6       **-2.13**   **0.0007**
                   **Ldlr**          -2.14               0.02              6       **-1.42**   **0.006**
                   **Scd1**          -2.07               0.02              6       **-1.19**   **0.01**
                   Nrp1              -1.58 to -2.02      0.02 to 0.009     6       No change   
                   Mtap1B            -2.10               0.01              6       No change   
                   **Alcam**         -1.60 to -1.94      0.03 to 0.02      6       **-1.43**   **0.01**
                                                                                               
  **14 months**    **Reelin**        -2.41               0.007             3       **-2.1**    **0.008**
                   HSPA5             -1.48               0.004             3       -1.27       0.2
                   Hnrpdl            -2.20               0.005             3       -1.21       0.2
                   Tnrc6a            -1.43 to -1.57      0.004 to 0.0004   3       No change   
                   **Alcam**         -1.50 to -1.65      0.04 to 0.004     3       **-1.59**   **0.003**

Significant results are highlighted in bold; n = no. of transgenic mice used for QPCR verification, with an equal number of gender matched littermate controls.

Reduced axon growth of VEGF^δ/δ^motor neurones grown in vitro
-------------------------------------------------------------

Downregulation of genes involved in nervous system development and axonogenesis was observed in motor neurones of VEGF^δ/δ^mice. A functional correlation of this finding was demonstrated by the growth of primary motor neurones from VEGF^wt/wt^, VEGF^δ/*wt*^and VEGF^δ/δ^mice *in vitro*. Survival of primary motor neurone cultures grown under basal conditions for 7 days was unaffected by deletion of the hypoxia response element of the VEGF gene (data not shown). A significant reduction in the length of axons was observed in cultures of motor neurones homozygous for the HRE deletion, compared to wild-type motor neurones (472 ± 26 μm vs 562 ± 31 μm, p = 0.047; figure [6a](#F6){ref-type="fig"}). The outgrowth of dendrites was unaffected (p = 0.34; figure [6b](#F6){ref-type="fig"}).

![**The average length of the longest axonal process observed in primary motor neuron cultures isolated from E12.5VEGF^δ/δ^(n = 4), VEGF^δ/wt^(n = 14) and VEGF^wt/wt^(n = 8) mice (Figure 6a)**. These motor neurons were grown for 7 days on laminin with BDNF and CNTF. The average length of dendrites isolated from the same mice is also shown (Figure 6b). Asterisk indicates p \< 0.05.](1471-2164-11-203-6){#F6}

Discussion
==========

Upregulation of oxidative phosphorylation in presymptomatic mice
----------------------------------------------------------------

A small but significant upregulation of genes involved in the TCA cycle and oxidative phosphorylation was observed in VEGF^δ/δ^mice in presymptomatic stages. This finding is not in keeping with the \'chronic ischaemia\' hypothesis of neurodegeneration in the VEGF^δ/δ^mouse model: were motor neurones in a state of chronic oxygen deprivation due to reduced baseline neural blood flow, oxidative phosphorylation would have been downregulated. A similar upregulation of oxidative phosphorylation was seen in motor neurones in the SOD1 mouse model of ALS \[[@B21]\], and this may be a non-specific adaptation to cellular stress in the early stages of disease.

Transcriptional downregulation and changes in the regulation of gene expression
-------------------------------------------------------------------------------

One of the most marked changes observed in the VEGF^δ/δ^mouse model was transcriptional downregulation with disease progression, which was accompanied in late stage disease by a reduction in expression of genes involved in the regulation of gene expression, particularly mRNA processing. Similar transcriptional downregulation was observed in a study of the SOD1 mouse model of ALS \[[@B21]\], and in the ageing human brain \[[@B88]\]. The cause of this transcriptional downregulation is not known, although several mechanisms may be proposed. Firstly, it may be due to low level oxidative modification of nuclear DNA, which has been shown to accompany downregulation of gene expression in the ageing human brain \[[@B88]\]. Secondly, reduction in expression of VEGF could result in reduced induction of sequence-specific transcription factors, such as Fos, which was robustly downregulated in this study, with consequent downregulation of genes regulated by those factors \[[@B89],[@B90]\]. Thirdly, epigenetic modifications which cause suppression of gene expression, such as DNA methylation, increase with age and are accelerated in neurodegenerative diseases \[[@B91]\].

Downregulation of cholesterol metabolism at disease onset
---------------------------------------------------------

Five genes in the final committed pathway to cholesterol synthesis, and two receptors which bind cholesterol and transport it into the cells, were downregulated in the VEGF^δ/δ^mouse. Neuronal cholesterol is either synthesised by neurones or produced by astrocytes, bound to apolipoprotein E (APOE), and taken up by neurones via the low density lipoprotein receptor\[[@B92]\]. Cholesterol-rich lipid rafts in the growth cone are required for downstream signaling of adhesion molecules and guidance receptors during axon growth and guidance. Cholesterol stimulates the formation of synapses, and has important roles in synaptic function, and the release of neurotransmitters \[[@B93]-[@B96]\]. A recent study showed that the neurotrophic factor, BDNF, promotes synaptic development in cortical neurones via the stimulation of cholesterol biosynthesis \[[@B97]\], and the findings of this study suggest that VEGF may have a similar function. Cholesterol homeostasis is already implicated in the pathogenesis of neurodegenerative disease. There is a strong association between Alzheimer\'s disease and the APOE4 allele, which has reduced efficacy in cholesterol delivery to cells, and in stimulating neurite outgrowth \[[@B98]\]. Downregulation in the expression of genes involved in the cholesterol synthesis pathway is seen in cortical tissue of patients with Huntington\'s disease, and in mouse and cell models of the disease \[[@B99],[@B100]\].

Neurite outgrowth and synaptogenesis
------------------------------------

In adult mice, reduction in neural expression of VEGF, through deletion of its hypoxia-response element, causes downregulation of genes which are known to play a role in the growth of neuronal processes and formation of synapses during embryonic development. These include promoters of outgrowth of neuronal processes, components of neurotrophic signalling pathways, cell adhesion molecules, and the cholesterol synthesis pathway. The most significantly enriched functional gene categories at 5 months relate to axon extension and axon maintenance. This finding was supported by *in vitro*data: primary motor neurones from VEGF^δ/δ^mice show a significant reduction in axon outgrowth compared to their wild-type littermates. This effect of VEGF was specific to that neuronal compartment, with no effect on dendrite growth, or on cell survival. Exogenous VEGF protein stimulates axon outgrowth in cultures of primary motor neurones \[[@B20]\] although to a lesser degree than exogenous BDNF and CNTF. Despite addition of BDNF and CNTF to the primary neurone cultures in this study, axon outgrowth from VEGF^δ/δ^motor neurones was significantly reduced, indicating that the effect of VEGF on axonal outgrowth cannot be substituted for by the presence of other growth factors.

Differential expression of genes relating to the growth of neuronal processes, and formation of synapses was an unexpected finding in the adult animal, but there is growing evidence that changes involved in the plasticity of the nervous system and in the maintenance of neuronal networks in the adult animal recapitulate, to some degree, those underlying the formation of neuronal networks during development: cell adhesion molecules that mediate target recognition and synapse formation during embryogenesis also lead to changes in synaptic efficacy in the adult nervous system \[[@B101]\]; BMP signalling at the Drosophila NMJ is not only required for normal synaptic growth, but also for synaptic stabilization, via LIM kinase-1, and disruption of this pathway leads to synaptic disassembly and retraction \[[@B102]\]; the wnt signalling pathway maintains activity-dependent axon stability in adult olfactory neurones \[[@B103]\]; neurotrophins were first recognized as target-dependent survival factors for developing neurones during embryogenesis, but they have also been shown to promote synaptic stability and maintain neuronal processes in response to mechanical axonal injury \[[@B104]\].

Although the NMJ is considered a relatively stable structure, plasticity of the motor system is seen in response to changing physiological demands and to pathological conditions. Alterations in synaptic structure and function occur in the motor cortex, spinal cord and NMJ in response to exercise \[[@B105]-[@B107]\], while partial denervation or paralysis results in sprouting and reinnervation from adjacent nerve fibres \[[@B57]\]. The observation of fibre-type grouping in ageing muscle indicates that denervation and reinnervation of muscle fibres occurs with normal ageing \[[@B108]\]. Motor units differ in the plasticity of their synapses. Synapses formed on Fast Synapsing (FaSyn) muscle, or by fast-fatiguable (FF)-type motor units exhibit relatively little synaptic plasticity, compared to Delayed Synapsing (DeSyn) or slow (S)-type motor units. Motor units with less synaptic plasticity exhibit early susceptibility to loss in motor neurone degenerative disease, and in the SOD1 mouse model of ALS, a progressive impairment of stimulus-induced synaptic sprouting was observed over the course of the disease, suggesting that the absence of synaptic plasticity, and disease-induced synaptic loss are mechanistically linked \[[@B109],[@B110]\].

The transcriptional changes observed in VEGF^δ/δ^mice would be predicted to result in a reduced capacity for the morphological adaptations that occur during plasticity of the motor unit, resulting in increased vulnerability to degeneration. As neuronal processes and synapses are required continuously to retract and reform during the process of synaptic plasticity, downregulation of genes involved in neurite growth and synapse formation would be likely to result in gradual attrition of synapses and distal cellular processes. Synapse retraction causes loss of access of the neurone to trophic signals from target tissue. A recent study has shown that muscle hypermetabolism is sufficient to cause degeneration of NMJs, and subsequent loss of spinal cord motor neurones \[[@B111]\]. Although ALS is characterized pathologically by loss of motor neurone somata, and gliosis in the anterior horn of the spinal cord, these post mortem findings may not reflect changes occurring earlier in the disease. There is evidence in both human ALS and in mouse models, that motor neurone death occurs by the type of \'dying back\' axonal degenerative pathophysiology, that would be predicted in this model, with defects of neuromuscular transmission, end-plate denervation, and \'peripheral pruning\' of axons as the earliest observed events \[[@B112]-[@B114]\]. VEGF^δ/δ^mice similarly show relative preservation of spinal motor neurones, at stages of disease where there is marked axonal loss \[[@B1]\].

The relevance of this finding in the VEGF^δ/δ^mouse model of ALS to the human disease is unknown, but failure of synaptic plasticity has been proposed as a pathogenic mechanism in Alzheimer\'s disease \[[@B115]\]. A failure to maintain neuronal processes and synapses in the face of increasing demands of neuronal plasticity would explain two epidemiological observations in ALS: the associations between exposure to vigorous physical activity \[[@B116],[@B117]\] or skeletal fractures \[[@B118]\], and the risk of developing the disease.

An alternative hypothesis is that the pathogenic insult in VEGF^δ/δ^mice occurs during their development, when a lack of VEGF may lead to aberrant neuronal guidance and formation of neural networks. Subtle defects in neuronal positioning and in synaptic circuitry in VEGF^δ/δ^mice could result in reduced stability of synaptic connections, or a reduction in target-derived neurotrophic support, with consequent increased loss of motor neurones during ageing. This hypothesis is supported by the observation that embryonic motor neurones show a reduction in axonal outgrowth *in vitro*.

Conclusions
===========

Reduction in expression of VEGF, through deletion of a regulatory promoter region of the gene, results in adult-onset motor neurone degeneration that resembles human ALS. We have presented evidence here that this phenotype is accompanied by reduction in expression, from symptom onset, of the cholesterol synthesis pathway, and genes involved in nervous system development, including axonogenesis, synapse formation, growth factor signalling pathways, cell adhesion and microtubule-based processes. These findings raise the possibility that VEGF is required for the maintenance of distal neuronal processes in the adult animal, perhaps through promotion of remodelling of distal processes and synapses in the face of the demands of neuronal plasticity. A reduction in VEGF expression in VEGF^δ/δ^mice may lead to failure of the maintenance of neuronal circuitry, causing axonal retraction and cell death.
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